Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PM .72 vol 120
Patient advocacy experts gather to start a conversation on cancer immunotherapy in Canada - CNW
27-Mar-2017 14:00
Patient advocacy experts gather to start a conversation on cancer immunotherapy in Canada
Canada NewsWire
TORONTO, March 27, 2017
Inaugural patient summit brings together experts across oncology to collaborate on patient access to innovative cancer treatments and foster collaboration amongst patient groups and the medical community to improve patient outcomes
TORONTO, March 27, 2017 /CNW/ - The Immuno-Oncology Network for Patient Organizations today announced its inaugural Patient Leader Education Summit, scheduled for Friday, March 31 to Saturday, April 1, 2017 at the St. James Cathedral Centre in Toronto. The Summit will bring together some of Canada's leading patient advocates in oncology for a two-day meeting intended to educate and identify solutions to expand access to cancer immunotherapy treatments.
"Cancer immunotherapy medicines have been one of the greatest advancements in cancer treatment, allowing patients with metastatic and advanced disease a real chance of survival, and I am living proof of this reality," says Kathy Barnard, Founder and President at the Save Your Skin Foundation. "Now, we must unify the patient voice and empower patient advocates and patients to be fully engaged in healthcare decision-making, to work together with all the stakeholders involved towards solutions for a sustainable system, and to ensure that cancer patients have access to innovative cancer therapies."
A highlight of the event will be a discussion about the landscape of cancer therapy today and a look at the future of cancer therapy led by world-leading cancer immunotherapy researcher Dr. John Bell from the Ottawa Hospital. Dr. Bell will be joined by renowned medical oncologist Dr. Marcus Butler from the Princess Margaret Cancer Centre, University Health Network, where he is also the director of the immune monitoring laboratory.
"Cancer immunotherapy is a class of treatments which stimulate a person's own immune system to target and attack cancer cells," says Dr. John Bell. "Right now, immunotherapy treatments have been used in patients with melanoma, lung and kidney cancers, and research continues to extend their use to include different types of cancer. The possibility for immunotherapy has yet to be realized. We also continue to evolve our research in other areas of care, as we know immunotherapy won't work for everyone. Having a wide range of options for patients continues to be important."
"As the landscape in cancer treatment evolves to include cancer immunotherapy and other innovative treatment options, medical professionals have a responsibility to collaborate with patients and patient advocates to meet the current and future needs of patients," says Dr. Marcus Butler. "If we work together, we have the potential to improve access to treatments, companion diagnostics, and supportive care and, most importantly, ensure the highest safety and effectiveness of care for everyone."
Summit topics will include the importance of taking a patient-focused approach to care, a panel discussion about the role for patient advocates in the regulatory process, and issues of access to cancer immunotherapy and innovative treatments. The group will develop an action plan that will identify tangible areas of improvement in cancer care delivery.
The event will feature speakers offering diverse perspectives and opinions based on their experience, including:
Dr. Marcus Butler, Medical Oncologist, Princess Margaret Cancer Centre, University Health Network
Dr. John Bell, Researcher, The Ottawa Hospital
Monette Greenway, Principal & Co-Founder, Precision Rx-Dx
Imran Ali, Senior Manager, pan-Canadian Pharmaceutical Alliance (pCPA)
Scott Gavura, Director, Provincial Drug Reimbursement Cancer Care Ontario (CCO)
Alexandra Chambers, Director, pan-Canadian Oncology Drug Review (pCODR)
Marie Hotte, Scientific Coordinator, Institut national d'excellence en santé et en services sociaux (INESSS) via video
Heather Logan, Executive Director, Canadian Association of Provincial Cancer Agencies (CAPCA)
Dr. Reiner Banken, Senior Fellow, Institute for Clinical and Economic Review (ICER)
Joanne Castonguay, Research Director, Institute for Research on Public Policy (IRPP)
Dr. Femida Gwadry-Sridhar, Founder & CEO, Pulse Infoframe
Ryan Peck, Executive Director of the HIV & AIDS Legal Clinic Ontario (HALCO)
Martine Elias, Director Access, Advocacy & Community Relations, Myeloma Canada
About the Immuno-Oncology Network for Patient Organizations The Immuno-Oncology Network for Patient Organizations emerged when several patient organization leaders from across Canada began to discuss the needs for a collaborative strategy focused on access to cancer immunotherapy treatments for patients in Canada. The Immuno-Oncology Network for Patient Organizations is dedicated to raising awareness of the needs of cancer patients and their families. Our goal is to work together to promote greater education and understanding of therapies to ensure that Canadians have equal, timely access to these therapies, companion diagnostics, and supportive care.
Steering Committee members of the Immuno-Oncology Network for Patient Organizations include the following:
Kathy Barnard, Save Your Skin Foundation
Canadian Cancer Survivor Network
Heather Chappell, Kidney Cancer Canada
Annette Cyr, Melanoma Network of Canada
Martine Elias, Myeloma Canada
Elizabeth Lye, Lymphoma Canada
Christina Sit, Lung Cancer Canada
Barry Stein, Colorectal Cancer Association of Canada
SOURCE The Immuno-Oncology Network for Patient Organizations
Chinese drug approval boosts AstraZeneca's lung cancer hopes - Reuters News
27-Mar-2017 09:20:52
• Tagrisso approved for patients with mutated form of cancer
• Mutation very common China, opening big sales opportunity
• First drug approved under Chinese priority review pathway
Adds further details on drug, executive comment
By Ben Hirschler
LONDON, March 27 (Reuters) - AstraZeneca AZN.Lhas won approval for its lung cancer pill Tagrisso in China, a key market for the potential blockbuster medicine.
Tagrisso is designed to help cancer patients with certain genetic mutations that are very common in China and the regulatory green light boosts the British drugmaker's prospects in a key therapy area.
Lung cancer is a vital component of AstraZeneca's ambitious sales targets, set in 2014 in response to a takeover attempt by Pfizer PFE.N, with Tagrisso forecast to contribute $3 billion.
At the time, many analysts viewed the Tagrisso goal as unrealistic. Yet consensus forecasts have now risen to $2.8 billion for 2022, according to Thomson Reuters data, helped by its strong launch and the failure of some rival products.
Tagrisso sales last year totalled $423 million.
China is potentially the biggest market for the drug because 30 to 40 percent of Asian patients with non-small cell lung cancer have epidermal growth factor receptor mutated tumours that are receptive to Tagrisso, a far higher rate than in the West.
AstraZeneca's head of drug development, Sean Bohen, said in a statement on Monday announcing the drug's approval that China represented a "significant opportunity".
Tagrisso is the first drug approved under the China Food and Drug Administration’s priority review pathway, which offers a fast track to market for an innovative medicines.
The once-daily pill is currently used as a second-line therapy, after patients have tried older drugs like Roche's ROG.S Tarceva and AstraZeneca's own Iressa, although a clinical trial this year could prove its benefit in first-line use.
Beyond Tagrisso, investors are heavily focused on prospects for another clinical study testing a combination of two drugs in the hot area of immunotherapy, where AstraZeneca is chasing rivals such as Merck MRK.N, Bristol-Myers Squibb BMY.N and Roche.
Scientists are adopting a new battle plan in the war against cancer
http://www.businessinsider.com/scientists-are-adopting-a-new-battle-plan-in-the-war-against-cancer-2017-3?IR=T
Designing nanomedicine for immuno-oncology
Article (PDF Available) · February 2017 with 54 Reads
DOI: 10.1038/s41551-017-0029
1st Wen Jiang
34.82 · University of Texas MD Anderson Cancer Center
2nd Christina A von Roemeling
30.48 · Mayo Foundation for Medical Education and Research
+ 3
3rd Yuanxin Chen
Last Betty Y.S. Kim
30.36 · Mayo Clinic
Show more authors
Abstract
Two major obstacles facing cancer nanomedicine are the tendency of nanoparticles to be taken up by normal tissues and organs and the nanoparticles' inability to efficiently penetrate solid tumours. Although substantial efforts have been made to improve the intratumoural delivery of nanotherapeutics, many strategies have failed to produce meaningful clinical benefits. Recent advances in the field of immuno-oncology have led to drugs that boost the host's own immune system to fight cancer. In contrast to conventional therapies, which often target cancer cells, immunotherapies stimulate immune cells in ways that promote their recognition and the eradication of tumours. In this Perspective, we posit that this approach represents a new framework for cancer nanomedicine, and that immune-targeted nanomedicines could generate tumouricidal effects without the need to overcome the pathophysiological barriers that are intrinsic to the tumour microenvironment and that hinder nanoparticle delivery. The rational design of new immuno-oncology nanomedicines provides opportunities for developing the next generation of nanotherapeutics for cancer patients.
https://www.researchgate.net/publication/313579001_Designing_nanomedicine_for_immuno-oncology
Upfront Use of Next-Generation ALK Inhibitors in NSCLC
Panelists: Mark A. Socinski, MD, Florida Hospital Cancer Institute; Tracey L. Evans, MD, University of Pennsylvania; Alexander Drilon, MD, Memorial Sloan Kettering Cancer Center; Vali A. Papadimitrakopoulou, MD, The University of Texas MD Anderson Cancer Center; Jared Weiss, MD, UNC Lineberger Comprehensive Cancer Center
Published Online: Monday, Mar 20, 2017
http://www.onclive.com/peer-exchange/lung-adenocarcinoma-approaches/upfront-use-of-nextgeneration-alk-inhibitors-in-nsclc
Research at Banner MD Anderson aims to help immune cells fight cancer
https://www.bannerhealth.com/news/2017/03/research-at-banner-md-anderson-aims-to-help-immune-cells-fight-cancer
The next generation of cancer care: Working to defeat — and even prevent — the disease
https://www.statnews.com/2017/02/27/next-generation-cancer-care-working-defeat-even-prevent-disease/
Exosomes: From Garbage Bins to Promising
Therapeutic Targets
Mohammed H. Rashed 1,2, Emine Bayraktar 1,3, Gouda K. Helal 2
, Mohamed F. Abd-Ellah 2
Paola Amero 1
, Arturo Chavez-Reyes 4 and Cristian Rodriguez-Aguayo 1,5,*
1 Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston,
TX 77030, USA; rashedmm1977@gmail.com (M.H.R.); bayraktaremine34@gmail.com (E.B.);
PAmero@mdanderson.org (P.A.)
2 Department of Pharmacology and Toxicology, Faculty of Pharmacy, The University of Al-Azhar, Cairo 11754,
Egypt; goudahelal@gmail.com (G.K.H.); mohamedabd_ellah@yahoo.com (M.F.A.-E.)
3 Department of Medical Biology, Faculty of Medicine, The University of Gaziantep, Gaziantep 27310, Turkey
4 Centro de Investigación y Estudios Avanzados del IPN, Unidad Monterrey, Apodaca NL CP 66600, Mexico;
achavezr@cinvestav.mx
5 Center for RNA Interference and Non-Coding RNA, The University of Texas MD Anderson Cancer Center,
Houston, TX 77030, USA
* Correspondence: CRodriguez2@mdanderson.org; Tel.: +1-713-792-3508
Academic Editor: Martin Pichler
Received: 14 December 2016; Accepted: 27 February 2017; Published: 2 March 2017
https://www.google.at/url?sa=t&source=web&rct=j&url=http://www.mdpi.com/1422-0067/18/3/538/pdf&ved=0ahUKEwiGwdPxufLSAhVQKywKHYIJA6k4ChAWCCIwAg&usg=AFQjCNFMilf5zTs8kNrRcT8Rw5cW6wm6iQ
During apoptosis mitochondrial outer membrane permeabilization (MOMP) is often a point-of-no-return; death can proceed even if caspase activation is disrupted. cell types regardless of caspase activity. Importantly the presence of intact mitochondria correlated with cellular recovery following MOMP provided that caspase activity was blocked. Such intact mitochondria underwent MOMP in response to treatment of cells with the Bcl-2 antagonist ABT-737 suggesting that the resistance of these mitochondria to MOMP lies at the point of Bax or Bak activation. Thus iMOMP provides a critical source of intact mitochondria that permits cellular survival following MOMP. Introduction In response to most stimuli engagement of apoptosis involves mitochondrial outer membrane permeabilization (MOMP) which in turn leads to widespread activation of executioner caspases. The proteolytic activity of these caspases causes the physiological hallmarks of apoptosis including DNA fragmentation nuclear condensation phosphatidylserine externalization and plasma membrane blebbing (Taylor et al. 2008 While caspase activation is the defining characteristic of apoptosis cells that undergo MOMP but are prevented from activating executioner caspases by chemical Rabbit Polyclonal to SAA4.inhibitors or by genetic ablation of Apaf-1 or caspase-9 will nonetheless die (Amarante-Mendes et al. 1998 Haraguchi et al. 2000 McCarthy et al. 1997 Xiang et al. 1996 MOMP-dependent caspase-independent cell death (CICD) may be due to loss of mitochondrial function caused by MOMP and/or by release of mitochondrial proteins that can NVP-BVU972 kill a cell in a caspase-independent manner (Tait and Green 2008 Examples of the latter include AIF Omi/HtrA2 and Endonuclease G although their roles in mediating CICD remain controversial (Li et al. 2001 Susin et al. 1999 Suzuki et al. 2001 That CICD is dependent on MOMP is evidenced by observations that expression of anti-apoptotic Bcl-2 proteins (Haraguchi et al. 2000 or lack of the NVP-BVU972 pro-apoptotic Bcl-2 effectors Bax and Bak (Lum et al. 2005 prevents cell death. These findings have led to the view that MOMP represents a point-of-no-return for cell death. However this is not always the case. For example post-mitotic sympathetic neurons deprived of neurotrophic factor undergo MOMP but remain viable provided caspase activity is inhibited and growth factor is replenished (Deshmukh et al. 2000 Martinou et al. 1999 Recently we found that proliferating cells can also recover following MOMP. By employing a retroviral based cDNA screen for inhibitors of CICD we identified glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as being able to promote cellular survival following MOMP and allow clonogenic outgrowth (Colell et al. 2007 This protective effect of GAPDH was dependent upon its well-defined glycolytic role and a novel role in stimulating mitophagy in part through up-regulation of Atg12. The ability of cells to recover from MOMP has a variety of clinical implications including implications for oncogenesis. For example tumor cell lines often display reduced caspase activity owing to a lack of Apaf-1 expression apoptosome activity or caspase expression (Devarajan et al. 2002 Ferreira et al. 2001 Soengas et al. 2001 Wolf et al. 2001 Alternatively some tumors over-express inhibitor of apoptosis proteins (IAPs) that can directly inhibit caspase function (Krajewska et al. 2003 Tamm et al. 2000 Moreover expression of a dominant negative form of caspase-9 (which prevents caspase activation following MOMP) has been shown to enhance survival and proliferation of transformed cells (Schmitt et al. 2002 These studies suggest that tumor cells have developed means of inhibiting caspase activity downstream of MOMP. The ability of tumor cells to recover and proliferate NVP-BVU972 after MOMP would facilitate tumor cell survival and chemotherapeutic resistance. How mitochondrial repopulation occurs during cellular recovery from MOMP is unknown. Mitochondrial function is critical for survival following MOMP since only cells that maintain ??m are able to survive (Colell et al. 2007 Deshmukh et al. 2000 however in order to recover from MOMP and proliferate cells must either generate or already possess a source of healthy.
This entry was posted in MET Receptor and tagged NVP-BVU972, Rabbit Polyclonal to SAA4. onFebruary 1, 2017.
http://www.techbizstrategy.com/2017/02/01/during-apoptosis-mitochondrial-outer-membrane-permeabilization-momp-is-often-a-point-of-no-return/
Antimicrobial peptides/proteins (AMPs) are biologically energetic molecules with different structural properties that are made by mammals plant life insects ticks and microorganisms. may appear in your BMS-345541 HCl body anywhere. Skin cancer understanding and self-efficacy are essential to improve sunlight security behavior but far better preventative approaches may also be required. AMPs may provide a new prophylactic BMS-345541 HCl strategy against epidermis cancer tumor. Within this mini review we pull attention to the usage of insect AMPs for the avoidance and treatment of epidermis cancer tumor. can arrest the development of murine melanoma B16F10-Nex2 cells when implemented topically within a cream-based formulation. Gerashchenko et al Also. (2014) demonstrated that individual ß-defensin 2 (hBD-2) can inhibit the development of individual carcinoma cells by suppressing the appearance of B-Raf cyclin D1 and cyclin E causing the appearance of p21WAF1 and activating pRB. The higher abundance of adversely charged membrane elements such as for example sialic acidity phosphatidylserine and heparan sulfate makes cancers cells attract specific cationic amphipathic peptides (Wang et al. 2016; Riedl et al. 2011b). Especially phosphatidylserine in cancers cell membranes is normally targeted by temporin-1CEa an AMP in the Chinese dark brown frog (Wang et al. 2016). Temporin-1CEa induces cell loss of life in breast cancer tumor cells by launching pro-apoptotic factors in the mitochondria and in addition disrupts the plasma membrane by revealing phosphatidylserine raising plasma membrane permeability and inducing membrane depolarization (Wang et al. 2013). The energetic motifs of ACPs are brief therefore large-scale synthesis can be cost-effective. Certain ACPs not merely display intrinsic anticancer activity but also improve the strength of conventional medicines (Gaspar et al. 2013; Hancock et al. 2006;BMS-345541 HCl Silva et al. 2012). There are 196 entries in the Antimicrobial Peptide Data source (APD) (http://aps.unmc.edu/AP/database/antiC.php) describing peptides with anticancer activity. Many ACPs attain cell membrane disruption by lytic activity or induce apoptosis in tumor cells through mitochondrial harm oftentimes leaving regular mammalian cells unharmed (Coffelt and Scandurro 2008; Hilchie et al. 2011). This review discusses the focuses on and active systems of ACPs and shows their potential as both prophylactic and restorative reagents indicated for the avoidance and treatment of tumor. We also consider the addition of ACPs in makeup and personal maintenance systems especially sun safety lotions that could enhance safety against BMS-345541 HCl skin tumor through the elimination of nascent tumor cells before symptoms become apparent. The framework of ACPs Insect AMPs are cationic and amphipathic and even though the length series and structure can COL4A1 vary greatly most possess a relatively low molecular mass (≥10?kDa). The framework contains hydrophilic and hydrophobic areas and the web charge is extremely positive (Dennison et al. 2006). The framework of AMPs enables solid electrostatic binding with bacterial or fungal cell membranes and particular enveloped infections (Ramamoorthy and Hoskin 2008; Reddy et al. 2004) but ACPs likewise have the unique capability to bind tumor cell membranes. Many ACPs consist of six cysteine residues developing three intramolecular disulfide bonds that assemble into hairpin like a-helices ß-bedding or mixed constructions but some prolonged structures are also reported (Bulet and Stocklin 2005; Hoskin and Ramamoorthy 2008; Wang et al. 2013). The experience of ACPs AMPs could be designated to different classes relating to their varied physicochemical properties but just two general settings of action have already been referred to: membranolytic BMS-345541 HCl and non-membranolytic (Schweizer 2009). The experience of ACPs depends upon their physicochemical features like the major sequence secondary framework net electrical charge amphipathicity hydrophobicity and focus aswell as the structure of the prospective membrane (Adams et al. 2009; Reddy et al. 2004; Teixeira et al. 2012). The power of several AMPs to permeabilize BMS-345541 HCl cell membranes correlates using their antimicrobial actions e.g. regarding defensins and cecropins (Rahnamaeian 2011). Membrane disruption
http://bio-surfactant.com/2017/03/12/antimicrobial-peptidesproteins-amps-are-biologically-energetic-molecules-with-different-structural-properties/
Hyperprogression on Checkpoint Inhibition Immunotherapy
Technavio has published a new report on the global liquid biopsy market from
2017-2021.
Srinivas Sashidhar, a lead research analyst from Technavio, specializing in research on in-vitro diagnostics (http://www.technavio.com/industries/vitro-diagnostics?utm_source=T2&utm_medium=BW&utm_campaign=Media) sector, says, “To treat diseases like lung cancer and breast cancer at an early stage, liquid biopsies are performed, as they help in the detection of cancer. An increasing number of cancer cases will increase the need for liquid biopsy in the market. Skilled lab technicians are required to handle liquid biopsy systems such as polymerase chain reactions and assays.”
The global liquid biopsy market
(http://www.technavio.com/report/global-vitro-diagnostics-global-liquid-biopsy-market-2017-2021?utm_source=T2&utm_medium=BW&utm_campaign=Media) is expected to grow at a staggering CAGR of more than 20% in next few years. A liquid biopsy is a novel technology in the cancer diagnostic market, which has attracted many investors in the market. New entrants and small companies in the market such as GRAIL, Guardant Health, Inivata, and Pathway Genomics have received funding from various investors such as OrbiMed Advisors, Imperial Innovations, and IBM Watson Founders Fund. It helped these companies with multi-center clinical trials, product development, and enabled them to commercialize the products.
Request a sample report: https://goo.gl/ulnDDq (https://goo.gl/ulnDDq)
AH .725
Good Morning and have a nice weekend!
Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion- A New Role for the AXL Receptor Tyrosine Kinase
Abstract
With the clinical impact of CTLA-4 and PD-1/PD-L1 immune checkpoint therapies, widespread interest in cancer immunotherapy has been ignited. However, the rate and extent of clinical responses to approved therapies are limited and often non-existent in many solid tumors. This is partially because immune checkpoint therapies are most effective against T-cell inflamed tumors, and non-T-cell inflamed or T-cell excluded tumors remain a significant barrier. New strategies are needed to overcome immune resistance mechanisms that arise during tumor development which result in T-cell exclusion. Approaches may need to be combined with conventional therapies such as chemotherapy, radiotherapy, and molecularly targeted therapy and many clinical trials are ongoing. This review discusses the challenge of T-cell exclusion and innate oncologic pathways that contribute to this problem, including ß-catenin, STAT3, NF-?B, PTEN, and AXL tyrosine kinase. The GAS6/AXL pathway is of interest immunologically as it's targeting can lead to greater antitumor immune responses after radiation. In addition, several targeted therapies that are selective and non-selective for AXL are in preclinical and clinical development in AML and renal cell cancer. There remains much to learn but the future is bright for anti-AXL therapies, though effective combinations and their impact may not be realized for years to come.
Received January 21, 2017.Revision received February 10, 2017.Accepted March 8, 2017.Copyright ©2017, American Association for Cancer Research.
http://clincancerres.aacrjournals.org/content/early/2017/03/11/1078-0432.CCR-17-0189.full-text.pdf
TIM-3 as a Target for Cancer Immunotherapy and
Mechanisms of Action
https://www.google.at/url?sa=t&source=web&rct=j&url=http://www.mdpi.com/1422-0067/18/3/645/pdf&ved=0ahUKEwiI3Mb11-_SAhUEXCwKHQFiCc0QFgghMAI&usg=AFQjCNGGHlg3V78XT1lpfAuR9zTimoW8XQ
Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
Byun DJ1,2, Wolchok JD1,2, Rosenberg LM2, Girotra M1,2.
Author information
1Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, 10065 New York, USA.Weill Cornell Medical College, 1300 York Avenue, New York, 10065 New York, USA.
Abstract
Advances in cancer therapy in the past few years include the development of medications that modulate immune checkpoint proteins. Cytotoxic T-lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD1) are two co-inhibitory receptors that are expressed on activated T cells against which therapeutic blocking antibodies have reached routine clinical use. Immune checkpoint blockade can induce inflammatory adverse effects, termed immune-related adverse events (IRAEs), which resemble autoimmune disease. In this Review, we describe the current data regarding immune-related endocrinopathies, including hypophysitis, thyroid dysfunction and diabetes mellitus. We discuss the clinical management of these endocrinopathies within the context of our current understanding of the mechanisms of IRAEs.
http://www.nature.com/nrendo/journal/v13/n4/full/nrendo.2016.205.html#access
GREEN again
Growing popularity Of Global Lung Cancer Therapeutics Market For The
Period 2017 - 2020
Other prominent vendors
....
....
OSI Pharmaceuticals
Peregrine
PharmaMar
http://www.openpr.com/pdf/480084/Growing-popularity-Of-Global-Lung-Cancer-Therapeutics-Market-For-The-Period-2017-2020.pdf
or
http://www.medgadget.com/2017/03/growing-popularity-of-global-lung-cancer-therapeutics-market-for-the-period-2017-2020.html
PM .7099 vol. 500
European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma
Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma Implications for Immunotherapy
Department of Dermatology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland3Department of Pathology, Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center and Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland.
March 2017
? 1 Read
?
??
Importance: The programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway play an important immunosuppressive role in cancer and chronic viral infection, and have been effectively targeted in cancer therapy. Anal squamous cell carcinoma (SCC) is associated with both human papillomavirus and HIV infection. To date, patients with HIV have been excluded from most trials of immune checkpoint blocking agents, such as anti-PD-1 and anti-PD-L1, because it was assumed that their antitumor immunity was compromised compared with immunocompetent patients.
Objective: To compare the local tumor immune microenvironment (TME) in anal SCCs from HIV-positive and HIV-negative patients.
Design, Setting, And Participants: Anal SCC tumor specimens derived from the AIDS and Cancer Specimen Resource (National Cancer Institute) and Johns Hopkins Hospital included specimens. Tumors were subjected to immunohistochemical analysis for immune checkpoints (PD-L1, PD-1, LAG-3) and immune cell (IC) subsets (CD3, CD4, CD8, CD68). Expression profiling for immune-related genes was performed on select HIV-positive and HIV-negative cases in PD-L1+ tumor areas associated with ICs.
Main Outcomes And Measures: Programmed death-ligand 1 expression on tumor cells and ICs, PD-L1 patterns (adaptive vs constitutive), degree of IC infiltration, quantified densities of IC subsets, and gene expression profiles in anal SCCs from HIV-positive vs HIV-negative patients.
Results: Approximately half of 40 tumor specimens from 23 HIV-positive and 17 HIV-negative patients (29 men and 11 women; mean [SD] age, 51 [9.9] years) demonstrated tumor cell PD-L1 expression, regardless of HIV status. Median IC densities were not significantly decreased in HIV-associated tumors for any cellular subset studied. Both adaptive (IC-associated) and constitutive PD-L1 expression patterns were observed. Immune cell PD-L1 expression correlated with increasing intensity of IC infiltration (r?=?0.52; 95% CI, 0.26-0.78; P?<?.001) and with CD8+ T-cell density (r?=?0.35; 95% CI, 0.11-0.59; P?=?.03). Gene expression profiling revealed comparable levels of IFNG in the TME of both HIV-positive and HIV-negative patients. A significant increase in IL18 expression levels was observed in HIV-associated anal SCCs (fold change, 12.69; P?<?.001).
Conclusions And Relevance: HIV status does not correlate with the degree or composition of IC infiltration or PD-L1 expression in anal SCC. These findings demonstrate an immune-reactive TME in anal SCCs from HIV-positive patients and support clinical investigations of PD-1/PD-L1 checkpoint blockade in anal SCC, irrespective of patient HIV status.
https://www.pubfacts.com/detail/28334399/Association-of-HIV-Status-With-Local-Immune-Response-to-Anal-Squamous-Cell-Carcinoma-Implications-fo
Sensitization to tamoxifen by tanshinone IIA
in tamoxifen-resistant breast cancer cells in vitro
Published February 28,2017
http://www.ijcem.com/files/ijcem0044204.pdf
Inositol phosphates and phosphoinositides activate insulin-degrading enzyme, while phosphoinositides also mediate binding to endosomes
Eun Suk Songa,
HyeIn Janga,
Hou-Fu Guoa,
Maria A. Julianob,
Luiz Julianob,
Andrew J. Morrisc,
Emilia Galperina,
David W. Rodgersa,d,1, and
Louis B. Hersha,d,1
Author Affiliations
Edited by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved February 24, 2017 (received for review August 12, 2016)
http://www.pnas.org/content/early/2017/03/20/1613447114.abstract
That is new for me!
Small Cell Lung Cancer: Can Recent Advances in
Biology and Molecular Biology Be Translated into
Improved Outcomes?
https://www.researchgate.net/publication/292345488_Small_Cell_Lung_Cancer_Can_Recent_Advances_in_Biology_and_Molecular_Biology_Be_Translated_into_Improved_Outcomes
Received 27 October 2015; revised 3 January 2016; accepted 5 January 2016
Available online - 29 January 2016
bUniversity of Texas Southwestern Medical Center, Dallas, Texas
fMemorial Sloan Kettering Cancer Center, New York, New York
....and many others!!!!!!!!
Must be this:
Abstract Number: 574
Session: PO.IM02.02 - Checkpoints 1 Presentation Title: Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma
Presentation Day/Time: Sunday, April 2, 2017, 1:00 - 5:00 PM Eastern Location: Section 25
Poster Board Number: 8
Author Institutions: Memorial Sloan Kettering Cancer Center, New York, NY; Peregrine Pharmaceuticals, Inc., Tustin, CA
Abstract Number: 1651
Session: PO.IM02.08 - Tumor Microenvironment and Checkpoints Presentation Title: Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model
Presentation Day/Time: Monday, April 3, 2017, 8:00 - 12:00 PM Eastern Location: Section 27
Poster Board Number: 29
Author Institutions: Memorial Sloan Kettering Cancer Center, New York, NY; Peregrine Pharmaceuticals, Inc., Tustin, CA
Reuters
PM .6999
Avid Bioservices Receives Mutliple 2017 CMO Leadership Awards for Quality, Reliability, Capabilties, Expertise and Compatibility - MKW
23-Mar-2017 13:05
Avid Bioservices Receives Mutliple 2017 CMO Leadership Awards for Quality, Reliability, Capabilties, Expertise and Compatibility TUSTIN, CA--(Marketwired - Mar 23, 2017) - Avid Bioservices, Inc., a wholly owned subsidiary of Peregrine Pharmaceuticals, Inc. ( NASDAQ
:
PPHM
) (
NASDAQ
:
PPHMP
), today announced that the company has been named a recipient of the 2017
Contract Manufacturing Organization (CMO) Leadership Awards. Presented by the
industry publication Life Science Leader and based on market research and
surveys conducted by Industry Standard Research (ISR), these awards are
intended to honor those companies in the contract manufacturing space that
provide their customers with the industry's highest level of service. Now in
its 6th year, Life Science Leader's CMO Leadership Awards aim to provide
industry insiders with accurate and reliable customer feedback to assist them
in choosing a reputable partner for their development and manufacturing needs.
Avid received awards in the following categories:
Quality
Reliability
Capabilities
Expertise
Compatibility
"We have built our contract manufacturing business based on a commitment to exceeding our customers' expectations in the areas of technical expertise, service, and reliability. It is particularly gratifying to receive these CMO Leadership Awards as the winners are specifically determined based on feedback from those customers that we are working to serve daily," said Steven W. King, president and chief executive officer of Peregrine Pharmaceuticals and Avid Bioservices. "As we continue to grow our Avid business and expand both our manufacturing capacity and portfolio of state-of-the-art capabilities, we look forward to the opportunity to deliver our award-winning services to a broader range of biopharmaceutical customers."
For more information about Life Science Leader's CMO Leadership Awards, please visit: http://cmoleadershipawards.com/.
About Avid Bioservices
Avid Bioservices provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With over 15 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit www.peregrineinc.com.
Contacts:
Kelly Pisarev Lord
Avid Bioservices, Inc.
(800) 987-8256
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
Email Contact (http://www2.marketwire.com/mw/emailprcntct...)
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
Email Contact (http://www2.marketwire.com/mw/emailprcntct...)
© 2017 Nasdaq, Inc. All rights reserved.
nMKW7G9Pfa
© Thomson Reuters 2017. All rights reserved. More
RELATED STORIES
Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting PPHM.O
23-Mar-2017 12:05GNW
Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2017 and Recent Developments PPHM.O
13-Mar-2017 21:05GNW
Cytovance® Biologics Wins 2017 CMO Leadership Awards 002399.SZ
14-Mar-2017 10:00GNW
Peregrine Pharmaceuticals' (PPHM) CEO Steve King on Q3 2017 Results - Earnings Call Transcript PPHM.O PPHM.O
14-Mar-2017 01:14MIDTRD
Related
RELATED QUOTES
Name Last % Change
PEREGRINE PHARMA
0.687700
RELATED NEWS TOPICS
Business Sectors
Biotechnology & Medical Research (TRBC) [MRCH]
Healthcare (TRBC) [HECA]
Pharmaceuticals & Medical Research (TRBC) [PHMR]
Geographies
Americas [AMERS]
North America [NAMER]
United States [US]
More Topics
Company News [CMPNY]
News Announcements [NEWR]
Languages
English [LEN]
Peregrine Pharmaceuticals Announces Five Abstracts Accepted for Presentation at AACR 2017 Annual Meeting - GNW
23-Mar-2017 12:05
TUSTIN, Calif., March 23, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies, and advancing its proprietary R&D pipeline, today announced that four preclinical abstracts and one clinical abstract have been accepted for presentation at the Annual Meeting of the American Association for Cancer Research (AACR), to be held April 1 - 5, 2017 in Washington, D.C.
Peregrine scientists and collaborators will present positive findings from multiple studies of the company's phosphatidylserine (PS)-targeting antibodies in combination with other anti-tumor agents, including results from two Memorial Sloan Kettering Cancer Center studies that evaluate the use of a bavituximab equivalent in combination with immune stimulating therapies. The following abstracts will be presented:
Abstract Number: 574
Session: PO.IM02.02 - Checkpoints 1 Presentation Title: Phosphatidylserine targeting antibody in combination with tumor radiation and immune checkpoint blockade promotes anti-tumor activity in mouse B16 melanoma
Presentation Day/Time: Sunday, April 2, 2017, 1:00 - 5:00 PM Eastern Location: Section 25
Poster Board Number: 8
Author Institutions: Memorial Sloan Kettering Cancer Center, New York, NY; Peregrine Pharmaceuticals, Inc., Tustin, CA
Abstract Number: 1651
Session: PO.IM02.08 - Tumor Microenvironment and Checkpoints Presentation Title: Targeting phosphatidylserine in combination with adoptive T cell transfer eliminates advanced tumors without off-target toxicities in a melanoma preclinical model
Presentation Day/Time: Monday, April 3, 2017, 8:00 - 12:00 PM Eastern Location: Section 27
Poster Board Number: 29
Author Institutions: Memorial Sloan Kettering Cancer Center, New York, NY; Peregrine Pharmaceuticals, Inc., Tustin, CA
Abstract Number: CT159
Session: PO.CT02 - Phase III Clinical Trials and Phase II/III Clinical Trials in Progress
Presentation Title: IFN-? analysis in blood and tissue as a potential prognostic and/or predictive biomarker Presentation Day/Time: Monday, Apr 3, 2017 1:00 - 5:00 PM Eastern Location: Section 33
Poster Board Number: 25
Author Institution: Peregrine Pharmaceuticals, Tustin, CA
Abstract Number: 3652
Session: PO.IM02.05 - BITES Bispecifics and Checkpoints Presentation Title: Combinational activity of LAG3 and PD-1 targeted therapies is significantly enhanced by the addition of phosphatidylserine targeting antibodies and establishes an anti-tumor memory response in murine triple negative breast cancer
Presentation Day/Time: Tuesday, April 4, 2017, 8:00 - 12:00 PM Eastern Location: Section 26
Poster Board Number: 25
Author Institution: Peregrine Pharmaceuticals, Tustin, CA
Abstract Number: 3657
Session: PO.IM02.05 - BITES Bispecifics and Checkpoints Presentation Title: Phosphatidylserine-targeting antibodies enhance anti-tumor activity of a tumor vaccine in a HPV-induced tumor model Presentation Day/Time: Tuesday, April 4, 2017, 8:00 - 12:00 PM Eastern Location: Section 26
Poster Board Number: 30
Author Institutions: Immunovaccine, Inc., Halifax, NS, Canada; Peregrine Pharmaceuticals, Inc., Tustin, CA
Bavituximab is an investigational monoclonal antibody that targets PS. Signals from PS inhibit the ability of immune cells to recognize and fight tumors. Bavituximab is believed to override PS mediated immunosuppressive signaling by blocking the engagement of PS with its receptors as well as by sending an alternate immune activating signal. Previous studies demonstrated PS-targeting antibodies shift the functions of immune cells in tumors, resulting in multiple signs of immune activation and anti-tumor responses.
Peregrine's clinical development strategy for bavituximab currently focuses on small, early-stage, proof-of-concept trials evaluating the drug in combination with other cancer treatments. As part of this approach the National Comprehensive Cancer Network (NCCN) has awarded grants to support three different clinical trials of bavituximab treatment combinations. These trials will evaluate novel bavituximab combinations in glioblastoma, head and neck cancer, and hepatocellular carcinoma including an immunotherapy combination. Additionally, Peregrine continues to advance its pre-clinical collaboration with Memorial Sloan Kettering Cancer Center with the goal of evaluating combinations of bavituximab with other checkpoint inhibitors and immune stimulatory agents. The intent behind this strategy is to focus our research and development spending to further validate bavituximab's combination potential as we seek to advance the program though a pharmaceutical or biotechnology partner.
About Peregrine Pharmaceuticals, Inc. Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit www.peregrineinc.com.
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
GlobeNewswire, Inc. 2017
nGNXNQXYSa
© Thomson Reuters 2017. All rights reserved. More
RELATED STORIES
Peregrine Pharmaceuticals' (PPHM) CEO Steve King on Q3 2017 Results - Earnings Call Transcript PPHM.O PPHM.O
14-Mar-2017 01:14MIDTRD
Peregrine Pharmaceuticals Shares Rise 10% as Data Support Cancer Diagnostics Tool PPHM.O PPHM.O
09-Feb-2017 17:47MIDTRD
Peregrine to Report Financial Results for Third Quarter of Fiscal Year 2017 After Market Close on March 13, 2017 PPHM.O
06-Mar-2017 14:05GNW
Related
RELATED QUOTES
Name Last % Change
PEREGRINE PHARMA
0.687700
RELATED NEWS TOPICS
Business Sectors
Biotechnology & Medical Research (TRBC) [MRCH]
Healthcare (TRBC) [HECA]
Pharmaceuticals & Medical Research (TRBC) [PHMR]
Geographies
Americas [AMERS]
North America [NAMER]
United States [US]
More Topics
Company News [CMPNY]
News Announcements [NEWR]
Languages
English [LEN]
Cancer Science 2017 - Market Analysis
Cancer Science Market:
The global Cancer Science and Therapy market is estimated to grow at 17.6% CAGR to reach $52.2 billion by 2021. Breast cancer therapy is the largest market expected to reach $30.8 billion by 2016 at an estimated CAGR of 15%.
Rise in cancer incidences and access to modern therapeutics, population of aged people, increase in innovations, improvements and approvals promote growth of the market. Furthermore, efficiency and High process magnetize manufactures also contribute to the growth of the market. Major restraints are high price of therapies, change in reimbursement policies, and challenges faced in clinical trials.
CHART MISSING!
Market is segmented based on therapies i.e. Targeted cancer therapies (Hormone therapy, Signal transduction inhibitors, gene expression modulators, Apoptosis inducers etc.), Hormone therapies (Forms of hormone therapy), Immunotherapy (Monoclonal antibodies, Cancer vaccines, Non-specific immunotherapies), Chemotherapy.
Based on geography, market is segmented into North America (US, Canada), Europe, Asia and Rest of the world. Major players are focusing on marketing their products in emerging markets such as India, Japan, Brazil, and China. Oncology spending remains concentrated to America and Europe which totally accounts for 65% of the total market. Targeted therapies have increased their share of global oncology from 11 percent to 46 percent last year.
Major companies in the market include Dendreon, Galena Biopharma, Newlink genetics, Peregrine pharmaceuticals, Inovio pharmaceuticals.
Players are implementing new innovations, strategies, new product launches to gain a competitive edge.
http://cancer.global-summit.com/america/
Seniors with Early NSCLC May Benefit From SBRT
—And other news from the Multidisciplinary Thoracic Cancers Symposium
March 20, 2017
https://www.medpagetoday.com/hematologyoncology/lungcancer/64000
Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR+, HER2- advanced breast cancer: results from BOLERO-2
Mary Ellen Moynahan1, David Chen2, Wei He2, Patricia Sung1, Aliaksandra Samoila1, Daoqi You1, Trusha Bhatt1, Parul Patel2, Francois Ringeisen3, Gabriel N Hortobagyi4, Jose Baselga1 and Sarat Chandarlapaty1
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
2Oncology Precision Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA
3Global Medical Affairs, Novartis Pharma AG, Basel CH-4002, Switzerland
4Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
Correspondence: Dr ME Moynahan, E-mail: moynaham@mskcc.org
Current Understanding With Biomarkers in HCC
Panelists: Ghassan K. Abou-Alfa, MD, Memorial Sloan Kettering Cancer Center; Richard S. Finn, MD, UCLA; Laura M. Kulik, MD, Northwestern University Feinberg School of Medicine; R. Kate Kelley, MD, University of California-San Francisco; Riad Salem, MD, Northwestern University Feinberg School of Medicine
Published Online: Tuesday, Mar 21, 2017
http://www.onclive.com/peer-exchange/optimizing-liver-cancer/current-understanding-with-biomarkers-in-hcc#sthash.uJ7hmOh9.dpuf
http://www.onclive.com/peer-exchange/optimizing-liver-cancer/current-understanding-with-biomarkers-in-hcc
Molecular Tumor Board: Integrating Biomarker Analyses into Clinical Decision-Making Regarding the Use of Immune Checkpoint Inhibitors in Cancer Treatment
Monday, April 3, 2017, Washington, DC — 7:00 PM – 9:00 PM (Eastern Time)
David F McDermott, MD
Associate Professor of Medicine
Harvard Medical School
Director, Biologic Therapy and Cutaneous Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber Cancer Center
Boston, Massachusetts
Craig Moskowitz, MD
Clinical Director
Division of Hematologic Oncology
Attending Physician
Lymphoma and Adult BMT Services
Member, Memorial Sloan Kettering Cancer Center
http://m.researchtopractice.com/Meetings/MolecularTumorBoard2017
Professor of Medicine
Weill Medical College of Cornell University
New York, New York
Immunologic Checkpoint Blockade:Combinations and Mechanism
Monday, March 6, 2017
Plenary Session 1:
Opening Ceremony
O1.1 TAT 2017 Honorary Award Invited Lecture: Immunologic Checkpoint Blockade: Exploring Combinations and Mechanisms
Jedd Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY, USA
http://tatcongress.org/wp-content/uploads/2017/03/O1.1-TAT-Congress-Wolchok-final.pdf
http://tatcongress.org/presentations-tat-2017/
DEFINING TUMOR-IMMUNE INTERACTION
Modeling the Cyber War between the Immune System and Tumor Cells
Sam M. Hanash, M.D., Ph.D., Professor, Molecular Pathology, Division of Pathology/Lab Medicine, The University of Texas MD Anderson Cancer Center[/
http://www.nextgenerationdx.com/biomarkers-cancer-immunotherapy/
INTEGRATING BIOMARKERS IN CLINICAL TRIALS AND PATIENT CARE
The Genomic and Immunologic Determinants of Response to Head and Neck Cancer Immunotherapy
Rajarsi Mandal, M.D., Head and Neck Surgical Oncology Fellow, Department of Surgery, Memorial Sloan-Kettering Cancer Center
http://www.nextgenerationdx.com/biomarkers-cancer-immunotherapy/
The show must go on!